X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CM24 is a first-in-class clinical stage mAb targeting CEACAM1, a novel immune checkpoint inhibitor with significant potential to treat multiple cancers.
Lead Product(s): CM-24,Nivolumab
Therapeutic Area: Oncology Product Name: CM-24
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
The acquisition will provide Purple Biotech with an expanded portfolio of investigational tri-specific antibody compounds that target multiple antigens and offer the potential to further expand to additional targets.
Lead Product(s): Tri-specific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Immunorizon
Deal Size: $101.0 million Upfront Cash: $3.5 million
Deal Type: Acquisition February 02, 2023
Details:
This collaboration will evaluate the potential efficacy of the combination of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1 antibodies.
Lead Product(s): NT219,Undisclosed
Therapeutic Area: Oncology Product Name: NT219
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menashe Bar-Eli
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 26, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
